Abstract
New treatment modalities, such as immunotherapeutic strategies, may help improve the currently poor prognosis and outcome of patients suffering from lung cancer. However, thus far, lung cancer has not been considered an immune-sensitive malignancy. Now, there is increasing evidence that specific humeral and cellular anti-tumor immune responses can be evoked. This article reviews immunotherapeutic strategies that are already in clinical use or well-progressed in early clinical trials. A special focus is put on non-small cell lung cancer as the most frequent type of all lung cancers.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Review
MeSH terms
-
Antibodies / immunology
-
Cancer Vaccines / immunology
-
Cancer Vaccines / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / immunology
-
Clinical Trials as Topic
-
Humans
-
Immunotherapy* / trends
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / immunology
-
Lung Neoplasms / therapy*
-
Models, Biological
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
-
Receptor Protein-Tyrosine Kinases / metabolism
Substances
-
Antibodies
-
Cancer Vaccines
-
Receptor Protein-Tyrosine Kinases